[HTML][HTML] Complete remission on 18-fluorodeoxyglucose positron emission tomography/computed tomography after nivolumab treatment in a patient with indolent …
Most patients with Hodgkin lymphoma (HL) get a remission after induction chemotherapy
with or without radiation therapy (RT). However, relapse rates range from 10–20% in cases …
with or without radiation therapy (RT). However, relapse rates range from 10–20% in cases …
Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and …
A Aslan, T Aras, E Özdemir - Leukemia & Lymphoma, 2017 - Taylor & Francis
The programmed death-1 (PD-1) regulatory pathway is active in several tumors and a potent
immunotherapeutic target with PD-1 inhibitors. Nivolumab is an anti-PD-1 monoclonal …
immunotherapeutic target with PD-1 inhibitors. Nivolumab is an anti-PD-1 monoclonal …
A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.
P Armand, MA Shipp, J Kuruvilla, GP Collins… - 2016 - ascopubs.org
TPS7573 Background: Nivo is a human IgG4 monoclonal antibody immune checkpoint
inhibitor that targets programmed death receptor-1 (PD-1) on activated immune cells and …
inhibitor that targets programmed death receptor-1 (PD-1) on activated immune cells and …
Nivolumab induces impressive responses in relapsed/refractory classic Hodgkin lymphoma: Single institutional experience
R Dada, Y Zabani - Journal of Oncology Pharmacy Practice, 2019 - journals.sagepub.com
Objectives Cancer can escape the immune system through different mechanisms. One such
mechanism is the expression of program death ligand-1 which binds to PD-1 receptor on …
mechanism is the expression of program death ligand-1 which binds to PD-1 receptor on …
Back to life with checkpoint inhibitors in Hodgkin lymphoma
R Dada, J Zekri - Journal of Oncology Pharmacy Practice, 2018 - journals.sagepub.com
Cancer can escape the immune system through different mechanisms. One of which is the
expression of program death ligand-1 (PD-L1). This ligand binds to programmed cell death …
expression of program death ligand-1 (PD-L1). This ligand binds to programmed cell death …
[引用][C] Single Institution Experience with Nivolumab in Treatment of Patients with Relapsed or Refractory Hodgkin's Lymphoma
B Kašperová, M Ladická… - Clinical …, 2017 - clinical-lymphoma-myeloma …
Objective To report the first experience with Nivolumab in the management of patients with
R/R cHL in Slovakia. Design Retrospective analysis of patients with R/R cHL who received …
R/R cHL in Slovakia. Design Retrospective analysis of patients with R/R cHL who received …
Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
D Maruyama, Y Terui, K Yamamoto… - Japanese Journal of …, 2020 - academic.oup.com
Background Many patients with classical Hodgkin lymphoma show increased programmed
death-1 ligand expression in Reed–Sternberg cells. We report the final results of a phase II …
death-1 ligand expression in Reed–Sternberg cells. We report the final results of a phase II …
Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma
FZ Mokrane, A Chen, LH Schwartz, F Morschhauser… - Radiology, 2020 - pubs.rsna.org
Background CT and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT performances
following immune therapy are not well known in patients with relapsed or refractory Hodgkin …
following immune therapy are not well known in patients with relapsed or refractory Hodgkin …
Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies
L Dercle, FZ Mokrane, JM Schiano de Colella… - European Journal of …, 2019 - Springer
The paradigm of response in Hodgkin lymphoma (HL) was developed in cytotoxic
chemotherapies and its use as a reference model for immune-modulatory regimens, which …
chemotherapies and its use as a reference model for immune-modulatory regimens, which …
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in
approximately one-third of the responding patients, the disease relapses following …
approximately one-third of the responding patients, the disease relapses following …